Immatics N.V. (IMTX)
IMTX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | IMTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Germany |
| IPO year | Not reported by the screener |
| SEC CIK | 0001809196 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | Netherlands |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-03-05 |
| Cash and burn | 345.9M EUR cash; operating cash flow -44.2M EUR a quarter. | Report 2025-12-31 |
| Shares outstanding | 134,071,432 (2025-12-31); 121,550,169 a year earlier; 76,670,699 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2025-12-05 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2025-07-01 |
| Auditor | PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft, Stuttgart, Germany | PCAOB Form AP 2026-03-27 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $7.5M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | Not filed | -196.4M EUR | -176.6M EUR | 345.9M EUR | No debt tags | Needs four quarters | 20-F 2026-03-05 |
| FY 2024 2024-12-31 | Not filed | 15.2M EUR | -158.0M EUR | 236.7M EUR | No debt tags | Needs four quarters | 20-F 2026-03-05 |
| FY 2023 2023-12-31 | Not filed | -94.6M EUR | 18.2M EUR | 218.5M EUR | No debt tags | Needs four quarters | 20-F 2025-03-27 |
| FY 2022 2022-12-31 | Not filed | 27.7M EUR | 100.1M EUR | 148.5M EUR | No debt tags | Needs four quarters | 20-F 2025-03-27 |
| FY 2021 2021-12-31 | Not filed | -93.3M EUR | -84.7M EUR | 133.0M EUR | No debt tags | Needs four quarters | 20-F 2023-03-22 |
| FY 2020 2020-12-31 | Not filed | -211.3M EUR | -80.7M EUR | 207.5M EUR | No debt tags | Needs four quarters | 20-F 2023-03-22 |
| FY 2019 2019-12-31 | Not filed | -31.6M EUR | 71.0M EUR | 103.4M EUR | No debt tags | Needs four quarters | 20-F 2022-03-23 |
| FY 2018 2018-12-31 | Not filed | -31.4M EUR | 20.7M EUR | 39.4M EUR | No debt tags | Needs four quarters | 20-F/A 2021-10-28 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in EUR.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B2 | 2026-08-25 |
| Latest annual report | 20-F | 2026-03-05 |
| Latest quarterly / interim | 6-K | 2026-11-10 |
Source: SEC EDGAR submissions feed, 248 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.5% |
| 1 month | -6.4% |
| 3 months | -33.4% |
| Year to date | -39.1% |
| 1 year | -36.0% |
| From 52-week high | -46.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ODTX | Odyssey Therapeutics Inc. | $19.36 | +1.15% | $930.6M |
| MGTX | MeiraGTx Holdings plc | $8.74 | -4.79% | $854.2M |
| GLUE | Monte Rosa Therapeutics Inc. | $9.16 | -2.24% | $782.7M |
| PRME | Prime Medicine Inc. | $4.19 | -1.87% | $762.3M |
| AURA | Aura Biosciences Inc. | $7.22 | +1.55% | $751.4M |
| INBX | Inhibrx Biosciences Inc. | $77.66 | -6.77% | $1.1B |
| VOR | Vor Biopharma Inc. | $18.97 | -2.32% | $1.2B |
| SLDB | Solid Biosciences Inc. | $6.48 | -5.26% | $723.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier